about
Radiotherapy for neovascular age-related macular degenerationRadiotherapy for neovascular age-related macular degenerationCirculating anti-retinal antibodies as immune markers in age-related macular degenerationCan Novel Treatment of Age-Related Macular Degeneration Be Developed by Better Understanding of Sorsby's Fundus DystrophySystemic complement activation in age-related macular degenerationImprovement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration.Optical coherence tomography and electrophysiology in X-linked juvenile retinoschisis associated with a novel mutation in the XLRS1 gene.Fundus autofluorescence in patients with leber congenital amaurosis.Serum elastin-derived peptides in age-related macular degeneration.The complement system and age-related macular degeneration.Evolving European guidance on the medical management of neovascular age related macular degeneration.Estimation of systemic complement C3 activity in age-related macular degeneration.The ChromaTest, a digital color contrast sensitivity analyzer, for diabetic maculopathy: a pilot study.Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema.Micropulse diode laser photocoagulation for central serous chorio-retinopathy.Anti-VEGF therapy for choroidal neovascularisation previously treated with photodynamic therapy.Comparing fixation location and stability in patients with neovascular age-related macular degeneration treated with or without RanibizumabA pilot study on the combination treatment of reduced-fluence photodynamic therapy, intravitreal ranibizumab, intravitreal dexamethasone and oral minocycline for neovascular age-related macular degeneration.Matrix metalloproteinase biology applied to vitreoretinal disorders.Comparison of Optomap ultrawide-field imaging versus slit-lamp biomicroscopy for assessment of diabetic retinopathy in a real-life clinicQuality of fixation in eyes with neovascular age-related macular degeneration treated with ranibizumabGuidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).Factors affecting reading speed in patients with diabetic macular edema treated with laser photocoagulation.The significance of the complement system for the pathogenesis of age-related macular degeneration - current evidence and translation into clinical applicationEfficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study.Decreased thickness and integrity of the macular elastic layer of Bruch's membrane correspond to the distribution of lesions associated with age-related macular degeneration.Pharmacokinetic evaluation of pegaptanib octasodium for the treatment of diabetic edema.Optomap ultrawide field imaging identifies additional retinal abnormalities in patients with diabetic retinopathy.STRUCTURAL-FUNCTIONAL CORRELATION IN PATIENTS WITH DIABETIC MACULAR EDEMA.Screening for age-related macular degeneration using nonstereo digital fundus photographs.Two-wavelength fundus autofluorescence and macular pigment optical density imaging in diabetic macular oedema.Bruch's membrane and the vascular intima: is there a common basis for age-related changes and disease?Intravitreal pegaptanib for the treatment of ischemic diabetic macular edema.Looking beyond Lucentis on the management of macular degeneration.Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.Medical management for the prevention and treatment of diabetic macular edema.Retinal Biochemistry, Physiology and Cell Biology.The use of microperimetry in assessing visual function in age-related macular degeneration.Drusen classification in bilateral drusen and fellow eye of exudative age-related macular degeneration.Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials.
P50
Q24235406-B983600D-0751-41AB-B44E-F9E50763C5BBQ24246802-12B8322A-FE06-46AE-8899-6FCCED87BD78Q24682990-86DC1EEC-F401-401A-9338-D637E6E1B3ADQ26799529-1A7270B0-2529-4E90-8A32-85C11879E65AQ28285925-6B47DF41-87B4-425A-9784-5D17FE4811AEQ30872695-6565238E-CC1C-42CD-925F-F25CF5E967EDQ32058775-2467865D-1A21-4A2D-853A-6C00F96F5C31Q33205226-DD617229-83E9-4F2E-BD51-6E018DEB0EA0Q33222312-3E1E0273-1054-4F7D-9068-62F3C46E3477Q33231562-09571950-9A8C-4EE7-B9FE-A94197084736Q33255038-00ABE209-9607-4BDF-BA36-B1EC7C7F5FFEQ33281594-746A3B3E-CB4C-4E8F-9216-D5C3B5E42561Q33360452-987E0BFE-9F0F-4D6B-8D15-B52393C52209Q33389404-16559CF6-F7C8-40A5-A4DF-685BCCDBFCCAQ33514080-C4140067-0071-48B0-B8B7-21C9F267D725Q33515246-7AFAE695-B8E9-40E1-ADA6-4B7C989EC4ECQ33753878-7F8F4018-08F8-4C6F-B528-C969B9A953FAQ33811616-6E45860D-56E6-4DB6-A259-1305EE9BE51BQ33933063-13366475-3191-4300-BD48-B64E0C080862Q34005550-D083390E-12A9-41BE-A1A8-013E27C14AFCQ34020468-183EE7AA-C926-444B-9974-26633E7C023DQ34092454-03FFE138-5584-451C-A881-599BCB27BF4FQ34263727-C7347E17-C34E-48AC-B806-0895CF480DD8Q34588115-B8383368-085A-42C3-BE69-7044A12BB7FDQ34818910-E084A5A7-FB70-41FC-94C2-CA874A4DBF28Q35083573-5819F27B-3094-4ECF-9949-2BE9866CAD40Q35173079-76993DE5-DCF5-411A-904A-BE0E28C93393Q35595970-33303AD9-1AEC-407B-9DBC-EF27FECAB6FDQ36116804-40CCE394-6033-45FB-BB65-2EA8E97F52AEQ36128211-26343544-7D7E-409B-9CFF-28A57144D6F2Q36167145-E7356FA7-8184-4B65-B940-A5C6BCDAE8ECQ36266395-71C9B0CD-2B55-4451-B7AE-C1FF91DC4655Q36391018-4D468C80-22C6-4DA0-894A-42F5777CCF70Q37054887-EA238589-F6FB-4729-B22A-89E78BECEAC2Q38003860-8D7EB926-4614-41FD-9FFE-D527656B119FQ38130797-E28FE1E0-E433-4CEA-95F4-3D8DF8730B20Q38616512-27FE03E1-0BB4-489E-A33B-3CC64916DC43Q39349578-70394535-D252-48E6-90D5-EA5BAC0940EFQ39709576-FDECCBBB-AB38-4488-9ABC-649C70006DB5Q39785107-4F4D6454-AFA0-4DDD-9B86-C13C8D4D0E43
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ngaihang Victor Chong
@ast
Ngaihang Victor Chong
@en
Ngaihang Victor Chong
@es
Ngaihang Victor Chong
@nl
Ngaihang Victor Chong
@sl
type
label
Ngaihang Victor Chong
@ast
Ngaihang Victor Chong
@en
Ngaihang Victor Chong
@es
Ngaihang Victor Chong
@nl
Ngaihang Victor Chong
@sl
prefLabel
Ngaihang Victor Chong
@ast
Ngaihang Victor Chong
@en
Ngaihang Victor Chong
@es
Ngaihang Victor Chong
@nl
Ngaihang Victor Chong
@sl
P106
P1153
7004645690
P21
P31
P496
0000-0002-7693-522X